Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II

Current Neuropharmacology

Volumn 7, Issue 4, 2009, Pages 315-330

  Miller, R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antipsychotic drugs; Atypical antipsychotic agents; Cholinergic interneurones; D1 receptors; D2 receptors; Individualized dose; Muscarinic M1 receptors; Muscarinic M4 receptors; Neuroleptic drugs; Neuroleptic threshold

Indexed keywords

ACETYLCHOLINE; ANTIDEPRESSANT AGENT; BENPERIDOL; BENZATROPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYCLIC AMP; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR; FLUPERLAPINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; MESORIDAZINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUPROMAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ACETYLCHOLINE RELEASE; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANXIETY DISORDER; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART DISEASE; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PROLACTIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; PSYCHOMOTOR DISORDER; PSYCHOSIS; QUANTITATIVE ANALYSIS; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; VISUAL HALLUCINATION;

EID: 73649091724     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015909790031184     Document Type: Review

References (134)

1. Abenson, M.H. (1969) Drug withdrawal in male and female chronic schizophrenics. Br. J. Psychiatry, 115, 961-962.
2. Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., Weiss, R., Cooper, T.B., Mann, J.J., Van Heertum, R.L., Gorman, J.L., Laruelle, M. (2000) From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA, 97, 8104-8109.
3. Ahmed, S., Chengappa, R., Naidu, V.R., Bakes, R.W., Parapelly, H., Schooler, N.R. (1998) Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J. Clin. Psychiatry, 59, 472-483.
4. Balant-Gorgia, A.E., Eisele, R., Balant, L., Garrone, G. (1984) Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur. Arch. Psychiatry Neurol. Sci., 234, 1-4.
5. Bebbington, P., Wilkins, S., Sham, P., Jones, P., van Os, J., Murray, R.M., Toone, B., Lewis, S. (1996) Life events before psychotic episodes: do clinical and social variables affect the relationship. Soc. Psychiatry Psychiatr. Epidemiol., 31, 122-128.
6. Bigelow, L.B., Kirch, D.G., Braun, T., Korpi, E.R., Wagner, R.L., Zalcman, S., Wyatt, R.J. (1985) Absence of relationship of serum haloperidol and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol. Bull., 21, 66-68.
7. Bisset, A.F., Arshad, P., Morcos, M., Sridharan, B. (2002) Discontinuation of thioridazine. BMJ, 325, 967.
8. Bobba, R. (1997) Severe exptrapyramidal side effects when discontinuing clozapine and starting haloperidol. Can. J. Psychiatry, 42, 530.
9. Bolden, C., Cusack, B., Richelson, E. (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther., 260, 576-580.
10. Branford, D. (1996) Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. J. Intellect. Disabil. Res., 40, 322-329.
11. Brooks, J.O. (2001) Successful outcome using quetiapine in a case of treatment-resistant schizophrenia with assaultive behavior. Schizophr. Res. 50, 133-134.
12. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P. Wong, D.T. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
13. Caligiuri, M.P., Teulings, H.-L., Filoteo, J.V., Song, D., Lohr, J.B. (2006) Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. Human Movement Sci. 25, 510-522.
14. Chouinard, G. (1990) Severe cases of neuroleptic-induced supersensitivity psychosis, diagnostic criteria for the disorder and its treatment. Schizophr. Res., 5, 21-33.
15. Chouinard, G., Jones, B.D., Annable, L. (1978) Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry, 135, 1409-1410.
16. Chue, P., Welch, R. (2001) Combination risperidone and quetiapine therapy in refractory schizophrenia. Can. J. Psychiatry, 46, 86-87.
17. Cohen, B.M., Lipinski, J.F., Waternaux, C. (1989) A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology, 97, 481-488.
18. Conley, R.R., Kwelly, D.L., Nelson, M.W., Richardson, C.M., Feldman, S., Benhan, R., Steiner, P., Yu, Y., Khan, I., McMullen, R., Gale, E., Mackowick, M., Love, R. (2005) Risperidone, quetiapine and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin. Neuropharmacol., 28, 163-168.
19. Copolov, D.L., Link, C.G., Kowalcyk, B.A. (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204, 636, 'Seroquel') and haloperidol in schizophrenia. Psychol. Med., 30, 95-105.
20. Coppens, H.J., Sloogg, C.J., Paans, A.M.J., Wiegman, T., Vaalburg, W., Korf, J. (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol. Psychiatry 29, 629-634.
21. Corripio, I., Catafau, A.M., Perez, V., Puigdemont, D., Mena, E., Aguilar, Y., Carrio, I., Alvarez, E. (2005) Striatal dopaminergic D2 occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry, 29, 91-96.
22. Coryell, W., Miller, D.D., Perry, P.J. (1998) Haloperidol plasma levels and dose optimization. Am. J. Psychiatry, 155, 48-53.
23. Davies, S.J.C., Cooke, L.B., Moore, A.G., Potokar, J. (2002) Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ, 324, 1519-1524.
24. de Leon, J., Stanilla, J.K., White, A.O., Simpson, G.M. (1994) Anticholinergics to treat clozapine withdrawal. J. Clin. Psychiatry, 55, 119-120.
25. de Oliveira, I.R., de Sena, E.P., Pereira, E.L., Miranda, A.M., de Oliveira, N.F., Ribeiro, M.G., de Castro-e-Silva, E., Dardennes, R.M., Samuel-Lajeunesse, B. and Marcilio, C. (1996) Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J. Clin. Pharmacol. Ther., 21, 229-236.
26. Dewey, R.B., O'Suilleabhain, P.E. (2000) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology, 55, 1753-1754.
27. Dickson, R., Williams, R., Dalby, J.T. (1994) Dystonic reactions and relapse with clozapine discontinuation and risperidone initiation. Can. J. Psychiatry, 39, 184.
28. Dieterle, D., Eben, E., Einhaupl, K., Hippius, H., Klein, H., Rüther, E., Schmauss, M. (1984) The effect of fluperlapine in acute psychotic patients. Pharmacopsychiatry, 17, 57-60.
29. Doron, M., Meirav, B., Chava, P., Herzel, S., Giladi, N. (2006) Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis. Clin. Neuropharmacol., 29, 331-337.
30. Driscoll, P.H. (2002) Discontinuation of thioridazine: Primary care experience. BMJ, Rapid Response Section, 24th July, 2002. Davies, S.J.C., Cooke, L.B., Moore, A.G., Potokar, J. (2002) Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ, 324, 1519-1521.
31. Durst, R., Teitelbaum, A., Katz, G., Knobler, H.Y. (1999) Withdrawal from clozapine: the "rebound" phenomenon. Isr. J. Psychiatry Relat. Sci., 36, 122-128.
32. Eichenberger, E. (1984) Pharmacology of fluperlapine compared to clozapine. Arzneimittenforschung 34, 110-113.
33. Extein, I, Augusthy, K.A., Gold, M.S., Pottash, A.L, Martin, D., Potter, W.Z. (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol. Bull., 18, 156-158.
34. Farde, L., Nordström, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C., Sedvall, G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49, 538-544.
35. Fernandez, H.H., Friedman, J.H., Jacques, C., Rosenfeld, M. (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord., 14, 484-487.
36. Fernandez, H.H., Treischmann, M.E., Okun, M.S. (2005) Rebound psychosis: effects of discontinuation of antipsychotics in Parkinson's Disease. Mov. Disord., 20, 104-115.
37. Fischer-Cornelssen, K.A. (1984) Fluperlapine in 104 schizophrenic patients. Arzneimittelforschung, 34, 125-130.
38. Fitzgerald, P.B., Kapur, S, Remington, G., Roy, P., Zipursky, R.B. (2000) Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl), 149, 1-5.
39. Frankle, W.G., Gil, R., Hacket, E., Mawlawi, O., Zea-Ponce, Y., Zhu, Z., Kochan, L.D., Cangiano, C., Slifstein, M., Gorman, J.M., Laruelle, M., Abi-Dargham, A. (2004) Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl), 175, 473-480.
40. Friedman, J.H., Factor, S.A. (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord., 15, 201-211.
41. Friedman, J.H., Goldstein, S., Jacques, C. (1998) Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open label pilot study. Clin. Neuropharmacol., 21, 285-288.
42. Gardner, D.M., Baldessarini, R.J., Benzo, J., Zarante, C.A., Tohen, M. (1997) Switching between clozapine and risperidone treatment. Can. J. Psychiatry, 42, 430-431.
43. Gardos, G., Tecce, J.T., Hartmann, E., Bowers, P., Cole, J.O. (1978) Treatment with mesoridazine and thioridazine in chronic schizophrenia: I. Assessment of clinical and electrophysiological responses in refractory hallucinating schizophrenics. Compr. Psychiatry, 19, 517-525.
44. Garver, D.L., Dekirmenjian, H., Davis, J.M., Casper, R., Ericksen, S. (1977) Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am. J. Psychiatry, 134, 304-307.
45. Garver, D.L., Hirschowitz, J., Glickstein, G.A., Kanter, D.R., Mavroidis, M.L. (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J. Clin. Psychopharmacol., 4, 133-137.
46. Geaney, D.P., Ellis, P.M., Soper, N., Shepstone, B.J., Cowen, P.J. (1992) Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biol. Psychiatry, 32, 293.
47. Gefvert, O., Lundberg, T., Wieselgren, I.M., Bergstrom, M., Langstrom, B., Wiesel, F., Lindstrom, L. (2001) D2 and 5HT2a receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol., 11, 105-110.
48. Gonier, T., Schiele, B.C., Vestre, N.D. (1970) A comparison of haloperidol and thioridazine HCl in chronic treatment-resistant schizophrenics. Behav. Neuropsychiatry, 2, 47-54.
49. Haddad, P.M., Wieck, A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64, 2291-2314.
50. Heresco-Levy, U., Greenburg, D., Lerer, B., Dasberg, H., Brown, W.A. (1993) Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. J. Clin. Psychiatry, 54, 59-62.
51. Hollister, L.E., Traub, L., Prusmack, J.J. (1960) Use of thioridazine for intensive treatment of schizophrenics refractory to other tranquilizing drugs. J. Neuropsychiatry, 1, 200-204.
52. Janicak, P.G., Javaid, J.I., Sharma, R.P., Leach, A., Dowd, S., Davis, J.M. (1997) A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr. Scand., 95, 343-350.
53. Joyce, J.N. (1993) Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III Results in Parkinson's disease cases. Brain Res., 600, 156-160.
54. Juncos, J.L., Roberts, V.J., Evatt, M.L., Jewart, R.D., Wood, C.D., Potter, L.S., Joum, H.-C., Yeung, P.P. (2004) Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov. Disord., 19, 29-35.
55. Kaeser, H.E. (1986) Parkinson therapy 1985. Schweiz. Med. Wochenschr., 116, 801-804.
56. Kasper, S., Muller-Spahn, F. (2000) Review of quetiapine and its clinical applications in schizophrenia. Exp. Opin. Pharmacother., 1, 783-801.
57. Kelly, M.W., Perry, P.J., Coryell, W.H., Miller, D.D., Arndt, S.V. (1990) Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. Psychopharmacology (Berl.), 102, 514-520.
58. Kessler, R.M., Ansari, A.S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B., Meltzer, H.Y. (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology, 31, 1991-2001.
59. Kirch, D.G., Bigelow, L.B., Korpi, E.R., Wagner, R.L., Zalcman, S., Wyatt, R.J. (1988) Serum haloperidol concentration and clinical response in schizophrenia. Schizophr. Bull., 14, 283-289.
60. Klein, C., Prokhorov, T., Miniovich, A., Dobronevsky, E., Rabey, J. (2006) Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin. Neuropharmacol., 29, 215-219.
61. Knable, M.B., Heinz, A., Raedler, T., Weinberger, D.R. (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res., 75, 91-101.
62. Korsgaard, S., Noring, U., Gerlach, J. (1984) Fluperlapine in tardive dyskinesia and parkinsonism. Psychopharmacology (Berl.), 84, 76-79.
63. Krystof, J., Zyg, J., Mitkiewicz, S., Kaczynski, J. (1972) Withdrawal symptoms after long-term treatment. Pol. Med. J., 11, 189-195.
64. Kucharski, L.T., Alexander, P., Tune, L., Coyle, J. (1984) Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology (Berl.), 82, 194-198.
65. Küfferle, B., Tauscher, J., Asenbaum, S., Vesely, C., Podreka, I., Brücke, T., Kasper, S. (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl.), 133, 323-328.
66. Kuenstler, U., Juhnhold, U., Knapp, W.H., Gertz, H.-J. (1999) Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Res., 90, 31-39.
67. Lasky, J.J., Klett, C.J., Caffey, E.M., Bennett, J.L., Rosenbaum, M.P., Hollister, L.E. (1962) Drug treatment of schizophrenia: a comparative evaluation of chlorpromazine, chlorprothixene, fluphenazine, reserpine, thioridazine and triflupromazine. Dis. Nerv. Syst., 23, 698-706.
68. Laughren, T.P., Brown, W.A., Williams, B.W. (1979) Serum prolactin and clinical state during neuroleptic treatment and withdrawal. Am. J. Psychiatry, 136, 108-110.
69. Levinson, D.F., Simpson, G.F., Singh, H., Yadalam, K., Jain, A., Stephanos, M.J., Silver, P. (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch. Gen. Psychiatry, 47, 761-768.
70. Linkowski, P., Hubain, P., Frenckell, R., Mendlewicz, J. (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur. Arch. Psychiatry Neurol. Sci., 234, 231-236.
71. Magliozzi, J.R., Hollister, L.E., Arnold, K.V., Earle, G.M. (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am. J. Psychiatry 138, 365-367.
72. Mann, K., Bartels, M., Gartner, H.J., Schied, H.W., Wagner, W., Heimann, H. (1987) Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study. Pharmacopsychiatry, 20, 155-159.
73. Margolese, H.C., Chouinard, G., Beauclair, L., Belanger, H.C. (2002) Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol., 22, 347-352.
74. Margolese, H.C., Chouinard, G., Kolivakis, T.T., Beauclair, L., Miller, R., Annable, L. (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry, 50, 703-714.
75. Mauri, M.C., Laini, V., Boscali, L., Rudell, R., Salvi, V., Orlandi, R., Papa, P. (2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur. Psychiatry, 16, 57-63.
76. Mauri, M.C., Steinhilber, C.P.C., Marino, R., Invernizzi, E., Fiorentini, A., Cerveri, G., Baldi, M.L., Barale, F. (2005) Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur. Psychiatry, 20, 55-60.
77. Mavroidis, M.L., Kanter, D.R., Hirschowitz, J., Garver, D.L. (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berl.), 81, 354-356.
78. McEvoy, J.P., Butner, N.C., Hogarty, G.E., Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry, 48, 739-735.
79. McEvoy, J.P., Lieberman, J.A., Stroup, T.S., Davis, S.M., Meltzer, H.Y., Rosenheck, R.A., Swartz, M.S., Perkins, D.O., Keefe, R.S.E., Davis, C.E., Severe, J., Hsaio, J.K. for the CATIE investigators. (2006) Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment Am. J. Psychiatry, 163, 600-610.
80. Meisenzahl, E.M., Dresel, S., Frodl, T., Schmitt, G.J.E., Preuss, U.W., Rossmüller, B., Tatsch, K., Mager, T., Hahn, K., Möller, H.-J. (2000) D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J. Psychopharmacol., 14, 364-370.
81. Melkersson, K. (2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J. Clin. Psychiatry 66, 761-767.
82. Meltzer, H.Y. (1997) Clozapine withdrawal: serotonergic or dopaminergic mechanisms? Arch. Gen. Psychiatry, 54, 760-761.
83. Meltzer, H.Y., Matsubara, S., Lee, J.-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D2 and serotonin-2 pKi values. J. Pharmacol. Exp. Ther., 251, 238-245.
84. Meltzer, H.Y., Lee, M.A., Ranjan, R., Mason, E.A., Cola, P.A. (1996) Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl.), 124, 176-187.
85. Miller, R. (1984) Major psychosis and dopamine: controversial features and some suggestions. Psychol. Med., 14, 779-791.
86. Miller, R. (1989) Hyperactivity of associations in psychosis. Aust. N.Z. J. Psychyiatry, 23, 241-248.
87. Miller, R. (1997) Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 21, 1059-1094.
88. Miller, R. (2000) Journey through inner space: An autobiographial account of a psychotic illness. In: Edward, J. Ed., Trips and journeys: personal accounts of early psychosis. Melbourne, EPPIC.
89. Miller, R., Chouinard, G. (1993) Loss of striatal cholinergic neurons as a basis for tardive and L-Dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry, 34, 713-738.
90. Miodownik, C., Lerner, V., Kibari, A., Toder, D., Cohen, H. (2006) The effect of sudden clozapine discontinuation on management of schizophrenic patients: a retrospective controlled study. J. Clin. Psychiatry, 67, 1204-1208.
91. Mones, R.J., Elizan, T.S., Siegel, G. (1971) Analysis of L-DOPA induced dyskinesias in 51 patients with parkinsonism. J. Neurol. Neurosurg. Psychiatry., 34, 668-673.
92. Morgante, L., Epifano, A., Spina, E., Zappa, M., Di Rosa, A.E., Marconi, R., Basile, G., Di Raimondo, G., La Spina, P., Quattrone, A. (2004) Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol., 27, 153-156.
93. Neto, L.M.R., Müller-Spahn, F., Rüther, E., Scherer, J. (1988) Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry, 21, 226-231.
94. (a) Nyberg, S., Farde, L., Halldin, C. (1997) Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Arch. Gen. Psychiatry, 54, 953-958. (b) Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., Farde, L. (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5HT2a receptor occupancy in schizophrenic patients. Am. J. Psychiatry, 156, 869-875.
95. Palao, D.J., Arauxo, A., Brunet, M., Bernardo, M., Haro, J.M., Ferrer, J., Gonzalez-Monclus, E. (1984) Haloperidol: therapeutic window in schizophrenia. J. Clin. Psychopharmacol., 14, 303-310.
96. Pierre, J.M., Wirshing, D.A., Wirshing, W.C. (2004) High-dose quetiapine in treatment-refractory schizophrenia. Schizophr. Res., 73, 373-375.
97. Potkin, S.G., Shen, Y.C., Zhou, D.F., Parders, H., Shu, L., Phelps, B., Poland, R. (1985) Does a therapeutic window for plasma haloperidol exist? Psychopharmacol. Bull., 21, 59-61.
98. Raedler, T.J., Knable, M.B., Lafargue, T., Urbina, R.A., Egan, M.F., Pickar, D., Weinberger, D.R. (1999) In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res., 90, 81-90.
99. Ray, W.A., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K., Murray, K.T. (2001) Antipsychotics and the risk of sudden death. Arch. Gen. Psychiatry, 58, 1161-1167.
100. Richelson, E., Souder, T. (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci., 68, 29-39.
101. Rodriguez, J.J., Garcia, D.R., Pickel, V.M. (1999) N-Methyl-D-Aspartate receptors within single neurons in rat motor and limbic striatum. J. Comp. Neurol., 413, 219-231.
102. Sacchetti, E., Panariello, A., Regini, C., Valsecchi, P. (2003) Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week flexible-dose, single-blind, exploratory, pilot trial. Schizophr. Res., 69, 325-331.
103. Santos, J.L., Cabranes, J.A., Almoguera, I., Ramos, J.A., Vazquez, C., Angeles, F. (1989) Clinical implications of determination of plasma haloperidol levels. Acta Psychiatr. Scand., 79, 348-354.
104. Scatton, B. (1982) Further evidence for the involvement of D2 but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci., 31, 2883-2890.
105. Scholz, E., Dichgans, J. (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur. Arch. Psychiatry Neurol. Sci., 235, 60-64.
106. Seeman, P. (2002) Atypical antipsychotics: mechanism of action. Can. J. Psychiatry, 47, 27-38.
107. Seppälä, N., Kovio, C., Leinonen, E. (2005) Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs, 19, 1049-1055.
108. Shiovitz, T.M., Welke, T.L., Tigel, P.D., Anand, R., Hartman, R.D., Sramek, J.J., Kurtz, N.M. Cutler, N.R. (1996) Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr. Bull., 22, 591-595.
109. Shostak, M., Perel, J.M., Stiller, R.L., Wyman, W., Curran, S. (1987) Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity? J. Clin. Psychopharmacol., 7, 394-400.
110. Smith, R.C., Baumgartner, R., Burd, A., Ravichandran, G.K., Maudlin, M. (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol. Bull., 21, 52-58.
111. Sovner, R. (1995) Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: two case reports. Ment. Retard., 33, 221-225.
112. Sramek, J.J., Potkin, S.G., Hahn, R. (1988) Neuroleptic plasma concentrations and clinical response: in search of a therapeutic window. Drug Intell. Clin. Pharm., 22, 373-380.
113. Stanilla, J.K., de Leon, J., Simpson, G.M. (1997) Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J. Clin. Psychiatry, 58, 252-255.
114. Stevens, A., Mahal, A., Gaertner, H.J. (1992) Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia. Pharmacopsychiatria 25, 218-223.
115. Stoof, J.C., Verheijden, P.M.F.H., Leysen, J.E. (1987) Stimulation of D-2 receptors in rat nucleus accumbens slices inhibits dopamine and acetylcholine release, but not cyclic AMP formation. Brain Res., 423, 364-368.
116. Stroup, T.S., Lieberman, J.A., McEvoy, J.P., Swartz, M.S., Davis, S.M., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, C.E., Severe, J., Hsaio, J.K. for the CATIE investigators. (2006) Effectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry, 163, 611-623.
117. Tarsy, D., Baldessarini, R.J. (2006) Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov..Disord, , 21, 589-598.
118. Tauscher, J., Küfferle, B., Asenbaum, S., Tauscher-Wisniewski, S., Kasper, S. (2002) Striatal dopamine-2 receptor occupancy as measured with [I123]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotic and haloperidol. Psychopharmacology (Berl.), 162, 42-49.
119. Tauscher-Wisniewski, S., Kapur, S., Tauscher, J., Jones, C., Daskalakis, Z.J., Paptheodorou, G., Epstein, I., Christensen, B.K., Zipursky, R.B. (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J. Clin. Psychiatry, 63, 992-997.
120. Ulrich, S., Neuhof, S., Braun, V., Meyer, F.P. (1998) Therapeutic window of serum haloperidol concentrations in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry, 31, 163-169.
121. van Putten, T., Marder, S.R., Wirshing, W.C., Aravagiri, M., Chabert, N. (1991) Neuroleptic plasma levels. Schizophr. Bull., 17, 197-216.
122. Verghese, C., DeLeon, J., Nair, C., Simpson, G.M. (1996) Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol. Psychiatry, 39, 135-138.
123. Viguera, A.C., Baldessarini, R.J., Hegarty, J.D., van Kammen, D.P., Tohen, M. (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry, 54, 49-55.
124. Vital-Herne, J., Gerbino, L., Kay, S.R., Katz, I.R., Opler, L. (1986) Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics. J. Clin. Psychiatry, 47, 375-379.
125. Volavka, J., Cooper, T.B., Czobor, P., Meisner, M. (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorders. Arch. Gen. Psychiatry, 52, 837-845.
126. Walther, S., Baciu, D. (2006) No rebound psychosis in a case of switching from clozapine to quetiapine. Psychiatr. Prax., 33, 93-94.
127. Welge, J.A., Keck, P.E. (2003) Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a metaregression. Psychopharmacology (Berl.), 166, 1-10.
128. Wistedt, B., Johanidesz, G., Omerhodzic, M., Arthur, H., Bertilsson, L., Petters, I. (1984) Plasma haloperidol levels and clinical response in acute schizophrenia. Nord. Psykiatr. Tidsskr., 1, 9-13.
129. Woggon, B., Heinrich, K., Küfferle, B., Müller-Oeringhausen, B., Pöldinger, W., Rüther, E., Schied, H.W. (1984) Results of a multicentre AMDP study with fluperlapine in schizophrenic patients. Arzneimittelforschung, 34, 122-124.
130. Woggon, B., Beckmann, H., Heinrich, K., Linden, M., Krebs, E., Küfferle, B., Pflug, B., Rüther, E., Schied, H.W. (1986) Clinically relevant differences in the therapeutic profile of fluperlapine compared to haloperidol in the treatment of schizophrenic psychosis - results of a multicentre double-blind study. Pharmacopsychiatry, 19, 204-205.
131. Wolkin, A., Barouche, F., Wolf, A.P., Rotrosen, J., Fowler, J.S., Shiuo, C.-Y., Cooper, T.B., Brodie, J.D. (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry 146, 905.
132. Zeng, X.P., Le, F., Richelson, E. (1997) Muscarinic M4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol., 321, 349-354.
133. Zesiewicz, T.A., Borra, S., Hauser, R.A. (2002) Clozapine withdrawal symptoms in a Parkinson's disease patient. Mov. Disord., 17, 1365-1367.
134. Zimbroff, D.L., Kane, J.M., Tamminga, C.A., Daniel, D.G., Mack, R.J., Wozniak, P.J., Sebree, T.B., Wallin, B.A., Kashkin, K.B. and the Sertindole Study Group. (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry, 154, 782-791.